Slide 1: KemPharm Q3 2021 Results Call
| KemPharm Q3 2021 Results Call November 10, 2021
Slide 2: Cautionary Note Regarding Presentation Information
Cautionary Note Regarding Presentation Information This presentation may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking s
Slide 3: Q3 2021 Results Call Participants
Q3 2021 Results Call Participants Travis Mickle, Ph.D. R. LaDuane Clifton, CPA President & Chief Chief Financial Officer, Executive Officer Secretary & Treasurer Tr @=Fti (i i‘_OCOCOCOCOC~C~C~*~*~*é*é*é‘“‘“(“<“‘“‘C*O@*“QOOOOOOOOOs
Slide 4: KemPharm: Q3 2021 and Recent Highlights
KemPharm: Q3 2021 and Recent Highlights v Commercial launch on July 21, 2021; just 100 days into launch v Payor access significantly improving; over 50 million lives now have access to AZSTARYS v Multiple presentations for AZSTARYS and SDX at recent medical conferences ¥ Clinical trial with SDX unde
Slide 5: Specialty pharmaceutical company discovering and developing novel treatments for CNS diseases
Specialty pharmaceutical company discovering and developing novel treatments for CNS diseases
Slide 6: KemPharm Leverages its LAT Prodrug Technology to Improve Approved Drugs
KemPharm Leverages its LAT® Prodrug Technology to Improve the Attributes of Approved Drugs eo” ap are —_ —_ Approved Drug with Ligand Prodrugwith Cleaved Drug through Sub-Optimal Improved Attributes Human Metabolic Properties Process Select FDA-approved and widely prescribed drug for improvement, se
Slide 7: Partnered Assets Create the Potential For Near and Long-Term Value
Partnered Assets Create the Potential For Near and Long-Term Value + Commercially available AZSTARYS® Gurnet Point Methylphenidate ER ADHD Capital/Corium Royalties/sales milestones expected to start in 2022 and beyond - + Licensed Meth ieee ER ADHD amet Ron + Ready to enter clinical phase ae P + Tim
Slide 8: AZSTARYS Product Highlights
AZSTARYS® Product Highlights * 70% prodrug of d-MPH (serdexmethylphenidate, or SDX) co-formulated with 30% immediate release d- MPH + AZSTARYS® features and benefits o Indicated for the treatment of ADHD in patients 6 years of age and older o Can be administered with or without food o Capsule can be
Slide 9: AZSTARYS - U.S. Commercial Launch
ASTARYS® - U.S. Commercial Launch + July 2021, Corium, an affiliate of GPC, launched AZSTARYS (serdexmethylphenidate and dexmethylphenidate capsules) in the U.S. eo 100 days’ post-launch, momentum building among payors, patients, providers and prescribers: = No push-back from prescribers or patients
Slide 10: Serdexmethylphenidate (SDX) Opportunity
Serdexmethylphenidate (SDX) Opportunity + SDX provides an opportunity to explore indications outside ADHD o SDX is the only C-IV methylphenidate-based product; all others are C-Il o SDX has a unique PK profile allowing for gradual and continuous release throughout the day o No generic equivalent and
Slide 11: Clinical and Business Criteria will Guide Decisions on SDX Opportunities
Clinical and Business Criteria will Guide Decisions on SDX Opportunities * Once available, KemPharm will analyze the data, along with other business criteria to determine how to best prioritize the SDX-based product candidates in order to maximize shareholder value + Criteria include: o Clinical ris
Slide 12: Financial Update
Financial Update As of September 30, 2021
Slide 13: Q3 2021 Results; Balance Sheet Demonstrates Solid Financial Position
Q3 2021 Results; Balance Sheet Demonstrates Solid Financial Position + Revenue of $2.0M, derived primarily from consulting service fees + Net loss ($1.8M), or ($0.05) per basic and diluted share + Net operating loss was ($2.2M), which increased by $1.0M compared to Q3 2020 due to an increase in oper
Slide 14: Uplisting to The Nasdaq Global Select Market
Uplisting to The Nasdaq Global Select Market *« KemPharm’s common stock listing was moved up to The Nasdaq Global Select Market effective October 19, 2021 + Nasdaq Global Select Market recognized as having the highest initial listing standards of any exchange in the world o Consists of 1,450 stocks
Slide 15: KemPharm: Looking Ahead
KemPharm: Looking Ahead v Corium’s U.S. launch progressing as planned v 100 days in, and AZSTARYS has payor access for over 50 million lives and growing; momentumis building v Data from SDX trial expected before year-end ¥ Multiple potential paths forward will be fully assessed based on commercial p
Slide 16: KemPharm
ee | a KemPharm Leveraging our LAT® Prodrug Technology to Create Long-Term Value For additional information please contact: Maureen McEnroe mmcenroe@tiberend.com